SCHEMBL3942659

SCHEMBL3942659

CN1CCN(CC(=O)N(C)c2ccc(N/C(=C3\C(=O)Nc4cc(F)ccc43)c3ccc4nccnc4c3)cc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 1/20 0.41
MELK Q14680 6/20 0.39
FGFR1 P11362 5/20 0.37
KDR P35968 5/20 0.37
FLT1 P17948 4/20 0.37
PDGFRB P09619 4/20 0.37
PDGFRA P16234 3/20 0.37
FGFR3 P22607 3/20 0.37
FGFR2 P21802 2/20 0.37
FGFR4 P22455 2/20 0.37
FLT4 P35916 2/20 0.37
ABL1 P00519 2/20 0.37
CSF1R P07333 2/20 0.37
RET P07949 2/20 0.37
KIT P10721 2/20 0.37
NTRK1 P04629 1/20 0.37
NTRK3 Q16288 1/20 0.37
ALK Q9UM73 2/20 0.37
INSR P06213 1/20 0.37
FLT3 P36888 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5858309 1.00 AAK1 (0.41) AAK1MELKFGFR1KDRFLT1
SCHEMBL3935551 0.91 AAK1 (0.41) AAK1MELKFGFR1KDRFLT1
SCHEMBL3935565 0.91 AAK1 (0.41) AAK1MELKFGFR1KDRFLT1
SCHEMBL3944119 0.91 AAK1 (0.51) AAK1MELKFGFR1KDRFLT1
SCHEMBL5857017 0.91 AAK1 (0.51) AAK1MELKFGFR1KDRFLT1
SCHEMBL225029 0.88 AAK1 (0.46) AAK1MELKFGFR1KDRFLT1
SCHEMBL225028 0.88 AAK1 (0.46) AAK1MELKFGFR1KDRFLT1
SCHEMBL4497133 0.88 MELK (0.41) AAK1MELKFGFR1KDRFLT1
SCHEMBL4497129 0.88 MELK (0.41) AAK1MELKFGFR1KDRFLT1
SCHEMBL4501637 0.87 MELK (0.48) AAK1MELKFGFR1KDRFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1551830-B1 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS BOEHRINGER INGELHEIM PHARMA (DE) 2009-04-08 EP disclosed
US-7148249-B2 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-12-12 US disclosed
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments CDK1, CDK2, CDK3 AAK1 1459/4885MELK 290/4885FGFR1 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.